Shares of Vericel Corp. (VCEL), which gained more than 40% over the past month, hit a 52-week high of $60.16 last week.
This commercial-stage company is developing advanced therapies for sports medicine and severe burn care. It currently markets three products in the U.S. - MACI, Epicel, and NexoBrid.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com